Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Folate Receptor Alpha (FRα) Expression and Heterogeneity in Epithelial Ovarian Cancer

NCT07889843 is registered in ClinicalTrials.gov with Hellenic Cooperative Oncology Group as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07889843 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Folate Receptor Alpha (FRα) Expression and Heterogeneity in Epithelial Ovarian Cancer
Lead sponsor
Hellenic Cooperative Oncology Group
Phase
Observational
Overall status
Recruiting
Start date
July 10, 2026
Completion date
April 30, 2027
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

folate receptor alpha positive, high grade serous ovarian cancer

Arms

As registered; 1 arm.

  • Patients with High-Grade Serous Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

    This cohort includes approximately 200 eligible female patients aged 18 years or older diagnosed with high-grade serous ovarian, fallopian tube, or primary peritoneal cancer between 1 January 2001 and 30 July 2025. Patients are identified retrospectively from approximately 15 clinical sites in Greece affiliated with the Hellenic Cooperative Oncology Group.

    Historically collected Formalin-Fixed Paraffin-Embedded (FFPE) tissue samples obtained at the time of initial diagnosis and stored in the Hellenic Cooperative Oncology Group biobank will be analyzed centrally using the Ventana FOLR1 RxDx assay to determine Folate Receptor Alpha (FRα) expression.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • FRα-Positive Status Baseline

    Assessment of FRα-positive status at diagnosis, defined as ≥75% of viable tumor cells demonstrating moderate (2+) and/or strong (3+) membrane staining by immunohistochemistry.

Lead sponsor's other trials

Hellenic Cooperative Oncology Group, most recent start first.

Similar trials

Same condition (Ovarian Neoplasms) and phase, most recent start first.